Alpha-Ketoglutarate Reverses Cartilage Damage in Osteoarthritis via Epigenetic Reprogramming

Osteoarthritis affects hundreds of millions globally and currently has no disease-modifying treatment. This study uncovers a previously underappreciated axis linking glutamine (Gln) metabolism to OA pathogenesis and identifies alpha-ketoglutarate (αKG) as a potential therapeutic agent operating through epigenetic mechanisms.

Using Mendelian randomization, the researchers first established a causal genetic link between grade-1 obesity, OA, and reduced blood Gln levels. LC-MS metabolomics confirmed that Gln and glutamate (Glu) were the most downregulated amino acids in cartilage from DMM-operated mice, IL-1β-treated chondrocytes, and damaged human OA cartilage. Critically, exogenous Gln supplementation could not rescue intracellular Gln because the key transporter SLC1A5 and the rate-limiting enzyme GLS1 were transcriptionally silenced in OA. Levels of SLC1A5 and GLS1 inversely correlated with OA severity scores in human tissue.

Gain- and loss-of-function studies confirmed that defective glutaminolysis drives OA: chondrocyte-specific Gls1 knockout mice developed spontaneous cartilage degradation, while adenoviral overexpression of Slc1a5 or Gls1 in mouse knee joints protected against DMM-induced destruction. The mechanism behind gene silencing was epigenetic: OA pathogenic factors (IL-1β, mechanical stress, high-fat diet) increased H3K27me3 deposition on the promoters of Slc1a5 and Gls1, suppressing their transcription.

αKG supplementation (administered intraperitoneally or orally) protected cartilage in both DMM and high-fat diet OA mouse models in a manner independent of TCA cycle flux or HIF-1α. Mechanistically, αKG acted as a cofactor for the H3K27me3 demethylase Kdm6b, driving demethylation of not only glutaminolysis gene promoters—creating a positive feedback loop that rescued Gln metabolism—but also the promoter of Ube2o, an E2 ubiquitin-conjugating enzyme. Elevated Ube2o promoted K48-linked polyubiquitination of TRAF6, targeting it for proteasomal degradation and thereby suppressing NF-κB signaling. This reversed the pathological glycolytic shift and oxidative phosphorylation dysfunction characteristic of OA chondrocytes.

The study provides a coherent epigenetic-metabolic circuit: OA stressors → H3K27me3 accumulation → silenced glutaminolysis → αKG depletion → reduced Kdm6b activity → further H3K27me3 accumulation (feed-forward loop). αKG breaks this cycle by restoring demethylase activity, rescuing both metabolic genes and the anti-inflammatory Ube2o-TRAF6-NF-κB axis. Caveats include reliance on mouse models and in vitro systems, with full clinical translation pending human trials.